Moreover, we demonstrated that SIAIS562055 alone induced robust antitumor efficacy and exhibited synergistic activity when combined with KRAS inhibitors in KRAS-mutant cancers, including those with acquired resistance to KRAS inhibitors. Here, KRAS is linked to cancer.